DaVita Inc. (DVA) Earnings Call Transcript & Summary
May 5, 2026
What were the key takeaways from DaVita Inc.'s May 5, 2026 earnings call?
In the first quarter of 2026, DaVita Inc. reported strong financial results, with adjusted operating income of $482 million and adjusted EPS of $2.87, both exceeding expectations. The company raised its full-year guidance for adjusted operating income to a range of $2.15 billion to $2.25 billion and adjusted EPS to $14.10 to $15.20 per share, primarily driven by improved treatment volume forecasts and lower patient care costs. The solid performance in Q1 positions DaVita favorably for the remainder of the fiscal year, suggesting potential upside for the stock.
What topics did DaVita Inc. cover?
- Revenue Growth Acceleration: DaVita's revenue per treatment saw a year-over-year increase of approximately 4%, with management attributing part of this to timing effects. CEO Javier Rodriguez noted, "We delivered strong financial results ahead of our expectations with outperformance from each element of our U.S. dialysis trilogy; treatment volume, revenue per treatment and cost per treatment."
- Volume Growth Expectations: The company raised its full-year volume growth expectations from flat to a range of 25 to 50 basis points, citing better-than-expected mortality and patient transfers from clinic closures by Fresenius. "We anticipate that these transfers will contribute to positive treatment growth over the remainder of the year," said Rodriguez.
- Technology Investments: DaVita is actively investing in technology to enhance operational efficiency and clinical outcomes. The company is modernizing its data infrastructure and deploying AI solutions, which are expected to reduce administrative burdens and improve patient care. Rodriguez stated, "We're taking a disciplined approach to AI that we've been building towards for years, and we're seeing that groundwork translate into real impact."
- ACA Plan Enrollment Impact: Management indicated that ACA open enrollment is trending towards a slightly favorable outcome compared to prior expectations, although they maintained a cautious stance on the overall impact. Rodriguez mentioned, "It sounds like you're saying it was coming in better, but it sounds like the guidance hasn't changed yet for the year to get that right."
- Cost Management: Patient care costs per treatment remained flat compared to the previous quarter, with management noting better-than-expected productivity improvements. CFO Joel Ackerman highlighted that "patient care costs were lower than expected, largely as a result of better-than-expected productivity improvements."
What were DaVita Inc.'s May 5, 2026 results?
- Adjusted Operating Income: $482 million
- Revenue per Treatment: $17.50 (year-over-year RPT growth was approximately 4% in the quarter)
- Free Cash Flow: $140 million (null)
- Adjusted Operating Income Guidance: $2.15 billion to $2.25 billion (raised and narrowed from prior guidance)
- Adjusted EPS Guidance: $14.10 to $15.20 (raised from prior guidance)
- Leverage Ratio: 3.34x (well within our target leverage range of 3 to 3.5x)
DaVita's strong Q1 results and raised guidance indicate a positive trajectory for the company, driven by improved treatment volumes and effective cost management. Investors should monitor the ongoing impact of technology investments and ACA enrollment trends as potential catalysts for future growth, while also keeping an eye on the competitive landscape and market dynamics.
Earnings Call Speaker Segments
Nic Eliason
executiveThanks for joining us. This is our first quarter earnings call, and we're glad you're still following what's happening with the company. I'm Nic Eliason, and I serve as Group Vice President of Investor Relations. With me on the call are Javier Rodriguez, who is our CEO, and Joel Ackerman, our CFO. I want to point out that we might make forward-looking statements on this call as defined under the federal securities laws. Known and unknown risks and uncertainties apply to all such statements, and those factors could lead to actual results differing materially from what those forward-looking statements describe. To learn more about these risks and uncertainties, take a look at the press release for our first quarter earnings along with the filings we've submitted to the SEC. Those include our latest annual report on Form 10-K, every quarterly report on Form 10-Q filed after it, and any other documents we've subsequently filed with the SEC. The information we currently have forms the basis for our forward-looking statements, and aside from situations where the law requires it, we have no intention and accept no obligation to revise them. Beyond that, keep in mind that some of what we cover today involves non-GAAP financial measures. You can find a reconciliation between those non-GAAP measures and the closest comparable GAAP financial measures in the earnings press release we furnished to the SEC, which is also posted on our website. At this point, I'll hand things over to Javier Rodriguez.
Javier Rodriguez
executiveThank you, Nic. Good afternoon to all of you, and I appreciate you being on the call today. At DaVita, our cornerstone is clinical excellence, powered by operational discipline that generates lasting results. We've consistently produced outstanding clinical outcomes alongside robust financial performance, and this quarter follows that same pattern. To make sure we maintain and extend this base, we're making active investments in our future capabilities. Given a landscape that's changing quickly, we're pursuing a practical strategy for growing our IT systems and digital infrastructure. The purpose of these focused technology investments is to enable our clinical teams and act as a foundation for our coming phase of clinical and operational excellence. Today, I'll cover our first quarter results, explain how technology is improving our operations, give an update on ACA plans, and wrap up with our outlook for the rest of the year. First, I'll begin, as we always do, with a clinical highlight; this quarter, the focus is on the ongoing momentum of Integrated Kidney Care, or IKC, our value-based care business. According to the most recent results from CMS's Comprehensive Kidney Care Contracting Program, or CKCC, we achieved year-over-year gains in all three key measurements, namely gross savings rates, total quality score, and high-performing status. From a clinical standpoint, this means our IKC care model, alongside our physician partners, is enhancing the health and wellbeing of our patients. On the economic side, we produced the largest total aggregate savings among all participants, fueled by our 4.5% improvement in gross saving rate since the program began. This clearly demonstrates how IKC clinical rigor combined with data-driven insights is generating better outcomes for our patients and a more sustainable model for the future of kidney care. Moving to the first quarter, we posted a strong financial result that beat our expectations, with outperformance from every element of our U.S. dialysis trilogy: treatment volume, revenue per treatment, and cost per treatment. This balanced outperformance shows the strength of our team and our commitment to consistent execution. I'll mention a few key metrics that contributed to the quarter and will help shape the rest of the year. Beginning with volume. During the first quarter, our treatment volume came in slightly above forecast. Quarter end census exceeded plan because mortality was better than forecasted, partly offset by admits that were lower than forecasted. Census also gained from patient transfers in tied to ongoing clinic closures by Fresenius. Even though it was negligible in first quarter volume, we expect these transfers to add to positive treatment growth over the rest of the year. Consequently, we're increasing our volume growth expectations for the full year from flat to a range of 25 to 50 basis point increase. Roughly half of the increase comes from better underlying performance, half is tied to transfer in from Fresenius. Moving to labor. Q1 beat plan, mainly due to better productivity, which we expect to maintain over the balance of the year. I'd like to move on to how we're approaching technology and where we're putting money to make our operations stronger and, in the end, improve what happens with patients. Our work with AI follows a careful, planned path that we've been working toward for quite a while, and that early effort is now producing genuine results. There are 2 pieces to what we're doing. The first is that we've upgraded the infrastructure behind our data. What that involves is making high-quality data uniform and connected throughout the company by way of tools such as our own EMR platform. That effort provides us a distinctive base for running AI applications at scale. The second piece is that we're putting AI solutions to work right now in clinical, operational, and business areas, aiming to help our caregivers, make our operations better, and produce results we can measure. Schedule Hub is one illustration — a brand-new tool that continuously handles shifts in every center's patient census, capacity, and teammate availability so it can suggest the best schedules for patients and staff as things happen. Because scheduling at our centers is so complicated, we anticipate this will cut the administrative load on our facility administrators and improve the teammate experience, all while helping patient care. That's just one of many instances in which the money we keep putting into IT turns into concrete benefits at scale across the company. Our AI efforts are still at an early stage, yet with the strength of our data foundation and how quickly we're deploying, we're in a good position to beat expectations both in clinical and operational terms as technology keeps changing. Now, about ACA plan enrollment. From what we know right now, ACA open enrollment is shaping up to be somewhat better than what we'd assumed before — we had expected a headwind of roughly $40 million in 2026. That improvement will be partly offset by more patients choosing bronze plans at lower levels, which means bigger out-of-pocket expenses and a small RPT headwind; we'll understand the enrollment result and the mix effect better as the year goes on. I'll wrap up my comments with the financial outlook for the rest of the year. Thanks to our first quarter results, we've begun the year well; we're lifting and tightening our guidance for adjusted operating income to a range of $2.15 billion-$2.25 billion. In the same way, we're lifting our adjusted EPS guidance to a range of $14.10-$15.20 per share. The higher guidance comes mostly from our increased volume forecast for the year along with lower patient care costs. I'll hand the call over to Joel now so he can go through our financial performance in greater detail.
Joel Ackerman
executiveThanks, Javier. To kick things off, I'll take you through what happened in Q1, and then I'll add some color on the 2026 guidance revision that Javier just mentioned. In the first quarter, adjusted operating income was $482 million. Adjusted EPS from continuing operations came in at $2.87, while free cash flow was $140 million. That adjusted operating income number landed about $50 million higher than our forecast. Roughly half of the beat was driven by performance coming in ahead of plan, with the other half attributable to timing. Let's start with the U.S. dialysis segment. Compared to the first quarter of 2025, treatments declined by about 20 basis points, but treatments per normalized day increased by 40 basis points versus Q1 of 2025, coming in roughly 20 basis points above our expectations. As Javier mentioned, we're lifting our full year volume guidance to 25 to 50 basis points. Just remember, that number reflects what we're forecasting for treatment growth; given the year-over-year headwind in treatments per normalized day for 2026 versus 2025, it works out to 50 to 75 basis points of growth in treatments per normalized day. Sequentially, revenue per treatment dropped by around $5, largely due to the usual first quarter pressure from patient pay responsibility. In the quarter, RPT increased roughly 4% compared with a year earlier, and our full-year expectation remains 1% to 2% growth. Per-treatment patient care costs were essentially unchanged from the fourth quarter. The primary driver was a seasonal drop following elevated health benefit costs during the fourth quarter, which was partly offset by the usual wage increases and other rising costs. Those patient care costs ended up below what we had anticipated, mostly because productivity gains came in stronger than expected. For U.S. dialysis G&A, costs fell by $16 million relative to the seasonally high fourth quarter, but compared with the first quarter of 2025 they were up roughly $37 million, or 13%. Ongoing technology investment accounts for that increase. Now let's look at the remaining business units. For Q1, adjusted operating income outside the U.S. came to $30 million, while IKC posted an adjusted operating loss of $19 million — neither figure surprised us. On the capital allocation front, we bought back 3 million shares in Q1, plus another 2 million after the quarter closed, and that latter figure counts the shares acquired from Berkshire Hathaway under our repurchase agreement. As of the close of Q1, our leverage ratio stood at 3.34x consolidated EBITDA, comfortably inside the 3x-3.5x target range we aim for. Moving past operating income, we saw other income of $4 million, which went up from the prior quarter largely because we stopped recording losses tied to our Mozarc investment. Our debt expense came to $145 million during the first quarter. Turning to guidance, we now anticipate that quarterly debt expense for the rest of the year will look like what we saw in Q1, driven by more share repurchases and higher expected interest rates, which means full-year debt expense should end up roughly level with last year. Regarding our 2026 guidance, as Javier described, we're raising the midpoint of our adjusted operating income outlook by $40 million. The largest portion of that bump comes from our expectations for higher treatment volume. Number two involves our expectation that labor efficiencies tied to inpatient care expenses will keep improving. Regarding the way that guidance spreads over the remaining months, right now our assumption is that adjusted operating income will land in approximately equal portions across the three quarters left in the year, which assumes IKC operating income carries more weight in Q4. We don't consider the seasonal pattern from 2025 to be representative. Our expectation is for phasing closer to the 2024 pattern. On EPS, we are similarly lifting our adjusted EPS guidance to match the updated range for adjusted operating income. That concludes what I had prepared to say today. Operator, we're ready to take questions.
Kevin Fischbeck
analystThanks, that helps. I'd like to go a bit deeper on what you said about volumes. Is there a way to tease apart the effect of weather and quantify it? And on the better mortality figure, could you separate how much of that stems from a mild flu season compared with a year earlier versus what's coming from underlying trends? I'm really trying to gauge how sustainable that improvement in mortality will be through the remainder of the year.
Joel Ackerman
executiveSure. Appreciate that, Kevin. Where weather is concerned, it landed right on our expectations. Naturally, weather gets factored into the forecast we put together. It varies from one year to the next. As I mentioned, it matched what we had projected. You could describe it as roughly 10 basis points favorable versus a year ago. On flu more broadly, once again it tracked with our plan. Our guidance at the start of the year assumed a flu season resembling the one from two years back. Even though the shape differed somewhat from quarter to quarter, the effect on us was essentially as anticipated. When it comes to flu, our main gauge is cumulative hospitalizations, available on the CDC website, since that drives volume impact for us; the current year matches what we observed two years ago. As for why mortality came in somewhat better than we projected, flu likely wasn't the reason, given that flu performed as expected. The driver was more related to underlying mortality.
Kevin Fischbeck
analystAll right, that's helpful. Could you elaborate a bit more on the rate revision? What made the rate come in so robust during the first quarter compared with what you're projecting for the full year?
Joel Ackerman
executiveOn rate, RPT rose slightly above 4%. Roughly $17.5, let's say. I'd characterize about two-thirds of that as typical items, meaning price increases and changes in mix. Around $6, approximately, I'd chalk up to timing. Some of it stemmed from unfavorable timing during the first quarter of 2025, while another portion came from favorable timing in the current year. Timing is something we frequently flag when it comes to RPT, and for the full year, we're maintaining our guidance of 1% to 2%.
Kevin Fischbeck
analystAll right. There's nothing out of the ordinary involving pharmaceuticals or binders or anything of that sort that might have distorted the figure?
Joel Ackerman
executiveNo, there was nothing out of the ordinary.
Kevin Fischbeck
analystAll right. Perhaps one final item. Could you expand a little on what the ACA is doing and what your thinking looks like there? I got the impression you were indicating things were landing ahead of expectations, yet it seems the outlook for the full year is still unchanged. Is that accurate? What's your read on how the timing works? Is the idea that the first quarter landed ahead of plan and you now expect it to build from here, or did you always figure Q1 would come in somewhat softer versus the rest of the year? Any perspective on that?
Javier Rodriguez
executiveYes. Kevin, that's a terrific question. The truth is we are still very early. To say it again, Q1 was roughly level with Q4, so it did better than what we had anticipated. Having said that, the truth is the effectuation rate and the affordability piece haven't yet shown how they'll shake out. It's too soon. We need to watch payments, and we need to watch enrollment as time goes on. That's the reason we feel it's somewhat premature to revise our figures. But the truth is we will need — the actual data point we're looking to see is the mix of our future incidents. That, naturally, is too soon to know. We're sticking with that 40 number, even though at present we would be trending toward a $40 million number. We're trending somewhat ahead of that.
Kevin Fischbeck
analystAll right, great. Thanks.
Javier Rodriguez
executiveThank you.
Andrew Mok
analystHello, good afternoon. I was hoping you might give us additional detail regarding the steps you're taking to put yourself in a position to win market share, plus the level of visibility you currently have into those share gains that led you to raise guidance — particularly as it relates to the clinic closures.
Javier Rodriguez
executiveWell, when all is said and done, we are obviously operating in a highly competitive marketplace. As for the centers being shut down, it's fair to presume they're small facilities, and it's equally fair to presume that Fresenius — or anybody else closing a location — would put in significant effort to retain those patients within their own network, alongside keeping the same physicians, and so on. Naturally, we're ensuring the market knows about our available chairs, our access to physicians, and everything else one would typically do in this situation. Ultimately, the patients and the physicians are the ones who will decide.
Andrew Mok
analystThanks. I simply wanted to ask more about what was said regarding mortality. I understand flu wasn't really the cause, but it would help to get some detail on how mortality actually performed underneath, since that measure matters a lot when it comes to building consensus and volumes for the rest of the year. Appreciate it.
Joel Ackerman
executiveThat measure does matter. You're completely correct on that point, Andrew. What I'd say is that the shifts are fairly minor, and we aren't prepared to identify any meaningful trend beneath the surface; having said that, we did raise the volume guidance, and that's reflected within it.
Andrew Mok
analystSo how did you manage to figure out that the cause was mortality and not some of those other things happening in the market, like flu and clinic shutdowns?
Joel Ackerman
executiveClinic shutdowns are a different matter, since those relate to admissions, and we have quite a bit of visibility into patients arriving and patients departing. When it comes to mortality, as we've noted previously, it can be a difficult variable to determine in real time, but now that we're here in May, we feel fairly confident about what we observed in Q1.
Javier Rodriguez
executiveAndrew, I believe I should jump in here and try to assist, since your question is a valid one. A number of factors feed into treatments. As you might expect, seasonality plays a role, mortality plays a role, admissions play a role, missed treatments play a role, transfers play a role, yet each of these is fairly minor. Our goal is, rather than pulling you into a realm of tiny figures, to hand you a range that accounts for all those variables.
Andrew Mok
analystGreat. Thank you.
Javier Rodriguez
executiveThank you.
Pito Chickering
analystHey, everyone. I appreciate you taking my question. To build on what was said about treatment, could you discuss the new starts to dialysis during the first quarter? When you consider Fresenius scaling in from their closures, does that happen as an immediate ramp in roughly 1Q and 2Q, followed by normalization in the back half of the year? I just want to confirm that while you're raising your treatment growth guidance, we're also modeling where things stand from 2Q onward and where you end up in the fourth quarter?
Joel Ackerman
executiveRegarding the admit side, I don't believe we have much detail to provide. We're discussing basis points of change, and then to take it to the next level and split that across all the inputs Javier mentioned, I think that leads us to false precision. As for the timing on the new starts, we observed what I'd estimate is roughly half the new starts from Fresenius that we'd see by the end of the first quarter; we'd estimate the remaining half will arrive in Q2. If you're considering how to model them, I would say we'll likely get about 2/3 of a year worth of those new starts.
Pito Chickering
analystSo, whenever you combine that with the new starts, the mortality, and Fresenius, roughly where do you expect us to finish the fourth quarter in terms of treatment, organic treatment growth?
Joel Ackerman
executiveYeah. Our framework is really treatments per normalized day, since that strips out the noise between quarters and years caused by differing day counts in a quarter and the varying blend of Monday, Wednesday, Friday versus Tuesday, Thursday, Saturday. Our expectation is that the normalized treatment per day count will rise as the year progresses. Right now it stands at roughly 40 basis points positive, and we anticipate that increasing throughout the year. To be sure everybody understands our approach, the new guidance we have for treatment volume is +25 to 50 basis points. Since there is a 25-day headwind this year on normalized treatment days, the guidance we have for the year would be +50 to 75 basis points of normalized treatments per day. That's 40 basis points at present moving up to that 50 to 75 basis point average for the year, finishing at some level above that.
Pito Chickering
analystAll right, excellent. Now a follow-up regarding revenue per treatment. If you exclude the $6 you mentioned from a timing standpoint, that brings us to $411 or $412. Normally there are two major step-ups — roughly $4 or $5 as deductibles get exhausted — and then the ramp continues into Q3. After that, in Q4, we obviously get the refresh from the new Medicare rates. I'm trying to understand how we still reach 1%-2% growth in revenue per treatment guidance, even after removing the $6 from Q1, given the usual seasonality you see in revenue treatment.
Joel Ackerman
executiveI believe two factors are at play. First is ordinary variability — the quarter ran somewhat higher, and you strip that out. The second factor involves mix and the enhanced premium tax credits. Our expectation is that commercial mix will fall throughout the year, which will weigh on RPT, and that should help you bridge from a larger Q1 figure to the 1%-2% for the full year.
Pito Chickering
analystAll right. So as of now, up through April, you still haven't observed those adverse effects that you're projecting — you're basically just presuming they'll show up as the year goes on?
Joel Ackerman
executiveRight.
Pito Chickering
analystAlright, final question. Regarding your G&A per treatment, you mentioned it rose 13% because of technology investments. Where does that land by year-end — should we expect a steady, straight-line decrease across the year as those investments get made, or can you give any guidance on how to model G&A cost per treatment through the year as tech spending starts to come down? Thank you.
Joel Ackerman
executiveThanks for asking about G&A. Let me assure you we're examining this with tremendous care. Looking at G&A on its own, that line is expanding more quickly than revenue. I believe it's useful to share our thinking here: we treat G&A as one element of overall cost; put differently, our aim isn't to fine-tune G&A, but instead to disregard where the expense sits so long as the combined pieces produce a solid figure. Considering our total cost over the past five years — covering patient care costs, depreciation, amortization, and G&A — the CAGR comes to 2.6%. We devote considerable effort to optimizing cost, and we focus less on its location within the P&L. In my view, our guidance will hold on our cost, meaning that 1.25%-2.25% we provided at the start of the year.
Pito Chickering
analystOK. That's excellent. Many thanks, and congrats on a strong quarter, everyone. I appreciate it.
Joel Ackerman
executiveThanks.
Dillon Nissan
analystHello, this is Dillon sitting in for Justin. Only two brief items from me. How did the commercial mix perform during the quarter? And on the Medicare Advantage front, I'm also interested — could you share a bit about how much share growth there was? Thank you.
Joel Ackerman
executiveYes. Appreciate that, Dillon. Both are essentially identical in answer. Compared with the prior quarter, they came in pretty much flat.
Javier Rodriguez
executiveGo ahead, Michelle.
A.J. Rice
analystHello, everyone. I might simply inquire about a few things referenced in the press release, to see if any of them warrant particular attention. You reference a year-over-year drop in health benefit expense and pharmaceutical cost, and then, on the G&A line, professional fees. Did that come in roughly as anticipated, or did something unusually favorable occur in that area? I'm just curious.
Joel Ackerman
executiveA.J., it came in as anticipated; quite often we observe a sequential decrease from Q4 into Q1, particularly when it comes to health benefits. There's nothing out of the ordinary there.
A.J. Rice
analystAll right. I value what you said regarding the tech investments and a few of the applications you're considering. Even knowing that any savings might get redirected elsewhere, can you give us some sense of the size of the opportunities you're seeing? Are they showing up in operating results at this point? How long do you think it will be before all of this starts to affect operating performance?
Javier Rodriguez
executiveYes, thanks for asking. Our perspective is the long-term one — once again, we're attempting to make sure our clinicians are set up as well as possible, and we're accepting a trade-off on efficiency for the long haul so that we can keep up our 3%-7% OI growth as time goes on. As you're aware, technology is advancing very rapidly at present, and a portion of this will be largely about user experience, meaning we're simply improving that experience. A portion of it will also contribute to the bottom line. It's somewhat early, and I don't believe we want to discuss the timing of it, but instead the sustainability and the outperformance of it.
A.J. Rice
analystOkay. Thanks a lot.
Javier Rodriguez
executiveThank you.
Ryan Langston
analystThank you, and good afternoon. It's encouraging to see the guidance for operating income raised, and the EPS outlook increased too. What caught my eye is that the free cash flow forecast stayed the same. I believe we saw a comparable situation a year ago. I just want to verify this reflects the usual pattern and isn't a signal of anything particular.
Javier Rodriguez
executiveCorrect. Ryan, your interpretation is on target. Free cash flow simply carries greater fluctuation and a broader span, which is why we left that figure unchanged even though OI went up.
Ryan Langston
analystAlright. Fraud, waste, and abuse are clearly top priorities for this administration. To me, it looks like dialysis could be somewhat more shielded than other provider categories. Any overall perspective on the administration's emphasis on that, FWA, and what it might potentially mean for DaVita, or possibly not mean for DaVita, or even just more generally for dialysis as a whole?
Javier Rodriguez
executiveYes. Appreciate the question. Commenting on the wider landscape is hard for us, but one thing I can state is that compliance is something we take extremely seriously. Second, one area where we get a bit of an advantage is that dialysis isn't a diagnosis people argue about. It's not as if there's a debate over whether someone should receive this treatment. That helps. Because it sits in a bundle within a single DRG, essentially, some compliance matters become less complicated. Once again, our internal attention is on ensuring we act properly toward the government.
Ryan Langston
analystExcellent. Thanks so much.
Javier Rodriguez
executiveAll right. I appreciate it, Michelle, and I want to thank everyone for being on today's call. Three closing points from me. To start, the clinical programs we've launched most recently are starting to build momentum, and we can already observe initial indications of what this means for the people we treat. Next, things are going nicely on the business side. Since we keep hitting our clinical targets, that fuels the solid numbers we're delivering financially. Last, we take a long-term perspective on what we do, and we will keep putting money into what lies ahead. Thanks to each of you for being part of this quarter. Take care, and we hope to see you again next time. Happy Cinco de Mayo to all of you.
Operator
operatorThanks for joining us, and that wraps up the call for today. At this point, feel free to hang up.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.